(PEG)-BHD1028

(PEG)-BHD1028 is a PEGylated peptide agonist of adiponectin receptors AdipoR1 and AdipoR2, designed to mimic the activity of the endogenous hormone adiponectin. The drug is a linear 15-amino acid peptide conjugated with a 5 kDa polyethylene glycol (PEG) moiety at the N terminus to improve solubility and pharmacokinetic properties. It activates key metabolic pathways including AMPK, p38 MAPK, and PPARα, leading to improved energy metabolism, mitochondrial biogenesis, anti-inflammatory effects, and epithelial protection. Preclinical studies have demonstrated its efficacy in models of dry eye disease (DED), type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity. In animal models of DED, it showed superior therapeutic effects compared to cyclosporine by improving tear volume and reducing inflammation. The drug was developed based on dual binding sites on adiponectin receptors for enhanced activity[1][2][3][4][5].

Other names

Pegylated-BHD1028Pegylated-BHD-1028Pegylated-BHD 1028